Cargando…

Strategies for Delivery of siRNAs to Ovarian Cancer Cells

The unmet need for novel therapeutic options for ovarian cancer (OC) deserves further investigation. Among the different novel drugs, small interfering RNAs (siRNAs) are particularly attractive because of their specificity of action and efficacy, as documented in many experimental setups. However, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Farra, Rossella, Maruna, Matea, Perrone, Francesca, Grassi, Mario, Benedetti, Fabio, Maddaloni, Marianna, El Boustani, Maguie, Parisi, Salvo, Rizzolio, Flavio, Forte, Giancarlo, Zanconati, Fabrizio, Cemazar, Maja, Kamensek, Urska, Dapas, Barbara, Grassi, Gabriele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835428/
https://www.ncbi.nlm.nih.gov/pubmed/31652539
http://dx.doi.org/10.3390/pharmaceutics11100547
_version_ 1783466669959544832
author Farra, Rossella
Maruna, Matea
Perrone, Francesca
Grassi, Mario
Benedetti, Fabio
Maddaloni, Marianna
El Boustani, Maguie
Parisi, Salvo
Rizzolio, Flavio
Forte, Giancarlo
Zanconati, Fabrizio
Cemazar, Maja
Kamensek, Urska
Dapas, Barbara
Grassi, Gabriele
author_facet Farra, Rossella
Maruna, Matea
Perrone, Francesca
Grassi, Mario
Benedetti, Fabio
Maddaloni, Marianna
El Boustani, Maguie
Parisi, Salvo
Rizzolio, Flavio
Forte, Giancarlo
Zanconati, Fabrizio
Cemazar, Maja
Kamensek, Urska
Dapas, Barbara
Grassi, Gabriele
author_sort Farra, Rossella
collection PubMed
description The unmet need for novel therapeutic options for ovarian cancer (OC) deserves further investigation. Among the different novel drugs, small interfering RNAs (siRNAs) are particularly attractive because of their specificity of action and efficacy, as documented in many experimental setups. However, the fragility of these molecules in the biological environment necessitates the use of delivery materials able to protect them and possibly target them to the cancer cells. Among the different delivery materials, those based on polymers and lipids are considered very interesting because of their biocompatibility and ability to carry/deliver siRNAs. Despite these features, polymers and lipids need to be engineered to optimize their delivery properties for OC. In this review, we concentrated on the description of the therapeutic potential of siRNAs and polymer-/lipid-based delivery systems for OC. After a brief description of OC and siRNA features, we summarized the strategies employed to minimize siRNA delivery problems, the targeting strategies to OC, and the preclinical models available. Finally, we discussed the most interesting works published in the last three years about polymer-/lipid-based materials for siRNA delivery.
format Online
Article
Text
id pubmed-6835428
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68354282019-11-25 Strategies for Delivery of siRNAs to Ovarian Cancer Cells Farra, Rossella Maruna, Matea Perrone, Francesca Grassi, Mario Benedetti, Fabio Maddaloni, Marianna El Boustani, Maguie Parisi, Salvo Rizzolio, Flavio Forte, Giancarlo Zanconati, Fabrizio Cemazar, Maja Kamensek, Urska Dapas, Barbara Grassi, Gabriele Pharmaceutics Review The unmet need for novel therapeutic options for ovarian cancer (OC) deserves further investigation. Among the different novel drugs, small interfering RNAs (siRNAs) are particularly attractive because of their specificity of action and efficacy, as documented in many experimental setups. However, the fragility of these molecules in the biological environment necessitates the use of delivery materials able to protect them and possibly target them to the cancer cells. Among the different delivery materials, those based on polymers and lipids are considered very interesting because of their biocompatibility and ability to carry/deliver siRNAs. Despite these features, polymers and lipids need to be engineered to optimize their delivery properties for OC. In this review, we concentrated on the description of the therapeutic potential of siRNAs and polymer-/lipid-based delivery systems for OC. After a brief description of OC and siRNA features, we summarized the strategies employed to minimize siRNA delivery problems, the targeting strategies to OC, and the preclinical models available. Finally, we discussed the most interesting works published in the last three years about polymer-/lipid-based materials for siRNA delivery. MDPI 2019-10-22 /pmc/articles/PMC6835428/ /pubmed/31652539 http://dx.doi.org/10.3390/pharmaceutics11100547 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Farra, Rossella
Maruna, Matea
Perrone, Francesca
Grassi, Mario
Benedetti, Fabio
Maddaloni, Marianna
El Boustani, Maguie
Parisi, Salvo
Rizzolio, Flavio
Forte, Giancarlo
Zanconati, Fabrizio
Cemazar, Maja
Kamensek, Urska
Dapas, Barbara
Grassi, Gabriele
Strategies for Delivery of siRNAs to Ovarian Cancer Cells
title Strategies for Delivery of siRNAs to Ovarian Cancer Cells
title_full Strategies for Delivery of siRNAs to Ovarian Cancer Cells
title_fullStr Strategies for Delivery of siRNAs to Ovarian Cancer Cells
title_full_unstemmed Strategies for Delivery of siRNAs to Ovarian Cancer Cells
title_short Strategies for Delivery of siRNAs to Ovarian Cancer Cells
title_sort strategies for delivery of sirnas to ovarian cancer cells
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835428/
https://www.ncbi.nlm.nih.gov/pubmed/31652539
http://dx.doi.org/10.3390/pharmaceutics11100547
work_keys_str_mv AT farrarossella strategiesfordeliveryofsirnastoovariancancercells
AT marunamatea strategiesfordeliveryofsirnastoovariancancercells
AT perronefrancesca strategiesfordeliveryofsirnastoovariancancercells
AT grassimario strategiesfordeliveryofsirnastoovariancancercells
AT benedettifabio strategiesfordeliveryofsirnastoovariancancercells
AT maddalonimarianna strategiesfordeliveryofsirnastoovariancancercells
AT elboustanimaguie strategiesfordeliveryofsirnastoovariancancercells
AT parisisalvo strategiesfordeliveryofsirnastoovariancancercells
AT rizzolioflavio strategiesfordeliveryofsirnastoovariancancercells
AT fortegiancarlo strategiesfordeliveryofsirnastoovariancancercells
AT zanconatifabrizio strategiesfordeliveryofsirnastoovariancancercells
AT cemazarmaja strategiesfordeliveryofsirnastoovariancancercells
AT kamensekurska strategiesfordeliveryofsirnastoovariancancercells
AT dapasbarbara strategiesfordeliveryofsirnastoovariancancercells
AT grassigabriele strategiesfordeliveryofsirnastoovariancancercells